Research graph
References from Combined Maximum Tolerated Activity and Lesion-based Dosimetry for Personalized Radioiodine Therapy in Metastatic Differentiated Thyroid Carcinoma: An Early Institutional Experience. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21660
10.3322/caac.21660 · External reference
2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer
10.1177/10507256251363120 · 2025 · External reference
EANM Dosimetry Commit-tee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy
10.1007/s00259-008-0761-x · 2008 · External reference
10.2967/jnumed.116.186866
10.2967/jnumed.116.186866 · External reference
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer
10.2967/jnumed.107.047159 · 2008 · External reference
Validation of a simple thyroid cancer dosimetry model based on the fractional whole-body retention at 48 hours post-administration of 131I
10.1089/thy.2014.0616 · 2015 · External reference
Association between radioactive iodine treatment for pediatric and young adulthood differenti-ated thyroid cancer and risk of second primary malignancies
10.1200/jco.21.01841 · 2022 · External reference
10.4274/2017.26.suppl.07
10.4274/2017.26.suppl.07 · External reference
The clinical effects of thyroid stun-ning after diagnostic whole-body scanning with 185 MBq 131I
10.1007/s00259-002-0945-8 · 2002 · External reference
